(Q38113674)

29 August 2017

title

Management of juvenile myoclonic epilepsy (English)

1 reference

29 August 2017

Arielle Crespel

1

1 reference

29 August 2017

Philippe Gelisse

2

1 reference

29 August 2017

Ronald C Reed

3

1 reference

29 August 2017

Edoardo Ferlazzo

4

1 reference

29 August 2017

Judith Jerney

5

1 reference

29 August 2017

Bettina Schmitz

6

1 reference

29 August 2017

Pierre Genton

7

1 reference

29 August 2017

publication date

1 July 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

28 Suppl 1

1 reference

29 August 2017

page(s)

S81-6

1 reference

Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Clinical factors of drug resistance in juvenile myoclonic epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Premature death in juvenile myoclonic epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Juvenile myoclonic epilepsy of Janz.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Juvenile myoclonic epilepsy: long-term response to therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Valproate monotherapy in juvenile myoclonic epilepsy: dose-related effects on electroencephalographic and other neurophysiologic tests

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Valproate as monotherapy for juvenile myoclonic epilepsy: dose-effect study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

The use of lamotrigine in juvenile myoclonic epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Lamotrigine for patients with juvenile myoclonic epilepsy following prior treatment with valproate: results of an open-label study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

When the first antiepileptic drug fails in a patient with juvenile myoclonic epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Outcome of lamotrigine treatment in juvenile myoclonic epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Antiepileptic drugs and pregnancy outcomes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Levetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Effects of levetiracetam on EEG abnormalities in juvenile myoclonic epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Levetiracetam in juvenile myoclonic epilepsy: long-term efficacy in newly diagnosed adolescents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Levetiracetam monotherapy in juvenile myoclonic epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized, double-blind, placebo-controlled studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Treatment options in juvenile myoclonic epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Topiramate in clinical practice: first year's postlicensing experience in a specialist epilepsy clinic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Topiramate in patients with juvenile myoclonic epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Topiramate or valproate in patients with juvenile myoclonic epilepsy: a randomized open-label comparison.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Topiramate for the treatment of juvenile myoclonic epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Neuropsychiatric profiles of patients with juvenile myoclonic epilepsy treated with valproate or topiramate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Effects of zonisamide on the electroencephalogram of a patient with juvenile myoclonic epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Efficacy and tolerability of zonisamide in idiopathic generalized epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Methsuximide therapy of juvenile myoclonic epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Antimyoclonic efficacy of piracetam in idiopathic generalized epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Clonazepam in juvenile myoclonic epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Lacosamide treatment of juvenile myoclonic epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Refractory idiopathic absence status epilepticus: A probable paradoxical effect of phenytoin and carbamazepine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Clinical and EEG asymmetries in juvenile myoclonic epilepsy (JME)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Exacerbation of juvenile myoclonic epilepsy with lamotrigine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

[Exacerbation of tonicoclonic seizures in a juvenile myoclonic epileptic taking lamotrigine]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Myoclonic status epilepticus in juvenile myoclonic epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Vigabatrin aggravates absences and absence status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Juvenile myoclonic epilepsy with recurrent myoclonic status: efficacy of valproate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Comparative safety of antiepileptic drugs during pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Effects of fetal antiepileptic drug exposure: outcomes at age 4.5 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy, and fetal outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Energy drinks and seizures: what is the link?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Visual stimuli in daily life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Suppressive efficacy by a commercially available blue lens on PPR in 610 photosensitive epilepsy patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Psychiatric comorbidity in juvenile myoclonic epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Psychiatric disorders in juvenile myoclonic epilepsy: a controlled study of 100 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Prognosis of juvenile myoclonic epilepsy is related to endophenotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Adjunctive behavioural treatment in adolescents and young adults with juvenile myoclonic epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Vagus nerve stimulation for refractory idiopathic generalised epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Is vagus nerve stimulation a treatment option for patients with drug-resistant idiopathic generalized epilepsy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

Seizure threshold in juvenile myoclonic epilepsy with Graves disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2013.01.001

10.1016/J.YEBEH.2013.01.001

7 January 2021

Identifiers

DOI

1 reference

29 August 2017

1 reference